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There are 3 members of the multidrug-resitance gene family expressed in mouse. Only one of these, mdrlb, and its gene product P-glycoprotein 
are induced to high levels in the mouse endometrium during pregnancy. It is shown here that P-glycoprotein in the gravid uterus is significantly 
larger (Mr 155000) compared to P-glycoprotein encoded by mdrlb in a murine multidrug-resistant cell line (M, 140000). However, both species 
co-migrate after enzymatic removal of N-linked sugars (Mr 125000). These results demonstrate that differential glycosylation of the mdrib gene 
product contributes to molecular heterogeneity found in P-glycoprotein from normal and multidr~g-resistant cells. 
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1. INTRODUCTION 
When mammalian tumor cells are selected in culture 
for resistance to a single antitumor agent of natural 
product origin, they will often display cross-resistance 
to a wide variety of structurally and functionally 
dissimilar chemotherapeutic agents. This type of 
multidrug resistance is due to the increased expression 
of specific members of a multigene family, termed mdr. 
The mdr genes encode a membrane glycoprotein, 
designated P-glycoprotein, which functions as an 
energy-dependent drug efflux pump with broad 
specificity (see [ 11). 
twe oligosaccharides which are added co- 
translationally. The 120- and 125-kDa precursors 
mature to their final molecular masses of approx. 130 
and 140 kDa, respectively, when the oligosaccharides 
are processed to complex-type sugar [6,7]. The mature 
protein is also phosphorylated [8- 111. 
In mouse, 3 genes comprising this multigene family 
have been identified [2-51 and have been designated 
mdrl [2], mdr2 [3] and mdr3 [4]. mdrl and mdr3, also 
known as mdrlb and mdrla [5], respectively, have been 
associated with the multidrug-resistance phenotype 
[2,5]. mdrl has been shown to confer multidrug 
resistance by transfection of its cDNA into drug- 
sensitive cells [Z]. Furthermore, independently isolated 
mouse multidrug-resistant cell lines that make P- 
glycoprotein encoded by either mdrla or mdrlb have 
been isolated [5]_ Mouse mdr2 is a highly homologous 
gene but does not appear to be capable of conveying 
multidrug resistance [3], In this report we will make use 
of the designations mdrla and mdrlb. 
mdr gene expression is dramatically increased in the 
gravid murine uterus 1121. The increased expression of 
P-glycoprotein is specifically localized to the luminal 
surface of the secretory epithelial cells within the en- 
dometrium. By using Northern blot analysis with gene 
specific probes, it has been demonstrated that the 
gravid endometrium expresses only mdrZb mRNA 
(referred to as mdrl in [4]). These results suggest hat 
the mdrlb gene product plays an important role during 
normal gestation. The endogenous ubstrate(s) for P- 
glycoprotein have not been identified. However, pro- 
gesterone may play a role in transport since it can in- 
teract with P-glycoprotein and reverse multidrug 
resistance [131. 
Although differential glycosylation of P- 
glycoprotein occurs in multidrug-resistant cell lines 
[6,7], little is known about P-glycoprotein gene pro- 
ducts in vivo. To this end, we compared P-glycoprotein 
from the uterus to that found in multidrug-resistant cell 
lines. 
mdrla and mdrlb encode 120- and 125kDa P- 
glycoprotein precursors, respectively [5,6]. These 
precursors contain approx. 5 kDa of high mannose 
2. MATERIALS AND METHODS 
2.1. Celi hes 
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Two 5774.2 mouse macrophage-like cells, designated J7.Vf-1 and 
J7.V3-1, were selected for resistance to vinblastine (VBL) and main- 
tained in drug [7]. J7.V1-1 and J7.V3-1 denote distinct, independent- 
ly isolated cell lines that are maintained in l.OpM drug. 
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2.2. Endometrial sample preparation 
C57Bl/6J mice were mated overnight and separated the next morn- 
ing which was considered to be gestation day 1. On day 15, mice were 
sacrificed and the uterus separated from the placenta and embryo. 
Microsomal membranes from the endometrium and plasma- 
membrane enriched subcellular fractions from multidrug-resistant 
cells were prepared as described [7,13]. 
2.3. Membrane preparation and Western blot analysis 
Membrane protein was solubilized in sample buffer (without 
heating; see [141), resolved by polyacrylamide gel electrophoresis [15] 
and transferred to nitrocellulose [16] or electroeluted. Blots were pro- 
bed as previously described with a polyclonal antibody, R3, specific 
for P-glycoprotein [7,17]. Electroeluted material was incubated with 
peptide N-glycosidase F (PNGaseF) for 16 h at 37°C [6], re- 
electrophoresed and transferred to nitrocellulose. 
3. RESULTS AND DISCUSSION 
P-glycoprotein from the gravid uterus and 
multidrug-resistant tumor cells were compared using 
the R3 antiserum. Fig.1 (left panel) demonstrates that 
P-glycoprotein from gravid uterus migrated with an M, 
of 155000 whereas the P-glycoprotein from the 
multidrug-resistant murine cell line, 57 .V 1- 1, migrated 
with an M, of 140000. No immunoreactive P- 
glycoprotein was observed with pre-immune serum 
(fig. 1, right panel). In addition, P-glycoprotein was not 
detected in the nonpregnant uterus, which is consistent 
with the very low levels of mdr mRNA detected ([12] 
and data not shown). Since it is known that P- 
glycoprotein in the endometrium and J7.V1-1 cells is 
encoded by mdrlb [4,5], these results suggested that 
compared to tumor cells in culture, the gravid uterus P- 
glycoprotein was differentially modified. 
To evaluate if post-translational N-linked glycosyla- 
tion was responsible for the differences in molecular 
weight that were observed, the deglycosylated species 
were compared. P-glycoprotein from the gravid uterus 
was compared with two multidrug-resistant cell lines, 
J7.V1-1 and J7.V3-1, which make P-glycoprotein en- 
coded by the mdrlb and mdrla genes, respectively [5]. 
The mature mdrlb gene product migrates at approx. 
140 kDa, while the mdrla gene product migrates at 
130 kDa. When enzymatically deglycosylated, the 
mdrlb and mdrla gene products migrate at 125 and 
120 kDa, respectively ([6,7] and fig.2). To make a com- 
parison between P-glycoprotein from the endometrium 
and multidrug-resistant cell lines, P-glycoprotein that 
had been resolved in gels was electroeluted and digested 
with peptide N-glycosidase F. This indirect procedure 
was necessary, since the protein degraded when total 
membrane preparations were digested directly. The 
deglycosylated protein was then resolved in gels and 
transferred to nitrocellulose in preparation for im- 
munoblot analysis. Fig.2 demonstrates that the 
deglycosylated form of P-glycoprotein from the gravid 
uterus co-migrated with the 125kDa deglycosylated 
species observed in the J7.V1-1 cell line and not with 
the 120-kDa species found in the J7.V3-1 cell line. 
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Fig.1. Western blot analysis of P-glycoprotein from gravid uterus 
and J7.V1-1 multidrug-resistant cells. Left panel shows anti-P- 
glycoprotein antiserum (I) binding to membrane preparations from 
(1) gravid uterus and (2) J7.V1-1 cells. Right panel shows pre-immune 
serum (PI) binding to membrane preparations from (1’) gravid 
uterus and (2’) J7.V1-I cells. Molecular mass marker positions are 
given on the left. 
Therefore, P-glycoprotein from the gravid uterus 
migrated at an apparent larger molecular weight 
because of differential N-linked glycosylation. 
It is most likely that differential glycosylation bet- 
ween P-glycoproteins from the endometrium and 
J7.V1-1 cells is due to unique processing of oligosac- 
charides on an identical amino acid backbone, since 
gene specific probes have been used to show that en- 
dometrial cells and J7.V1-1 cells encode P- 
glycoproteins derived from mdrlb [4,5]. The latter con- 
clusion has been confirmed with an antibody that is 
specific for the mdrlb gene product since this antibody 
recognizes endometrial P-glycoprotein (Hsu and Hor- 
witz, personal observation). A less likely alternative in- 
Source: V3 E VI E V3 VI 
PNGaseF: + + + - - - 
Fig.2. Western blot analysis of deglycosylated and native P- 
glycoprotein. The membrane preparations were treated with PNGase 
F (+) or enzyme buffer (-) as indicated. V3 and Vl indicate 
membrane preparations from multidrug-resistant cell lines J7.V3-1 
and J7.V1-1, respectively. E signifies a membrane preparation from 
gestation day 15 uterus. Molecular mass markers are given on the 
left. 
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terpretation is that both P-glycoproteins are encoded 
by mdrlb homologs in which there is diversity in the 
coding sequence in the region of N-linked glycosyla- 
tion. Alternate splicing, which has been observed in a 
homologous mdr gene found in human liver [ 181, could 
create such diversity. 
Differential N-linked glycosylation of the mdrlb 
gene product can increase the apparent molecular mass 
of the 125 kDa-precursor by lo-17 kDa in in- 
dependently isolated J774.2-derived multidrug- 
resistant cell lines [6,7]. It can also increase the mobility 
of the P-glycoprotein precursor expressed in hamster 
multidrug-resistant cells by 30 kDa [14]. It remains 
unclear if differences in glycosylation alter the capacity 
of P-glycoprotein to transport endogenous compounds 
or natural products. Some data suggest hat such dif- 
ferences may not generally influence the function of P- 
glycoprotein since lectin mutant cell lines can become 
multidrug resistant [ 191 and multidrug-resistant cells 
treated with tunicamycin remain resistant o vinblastine 
[20]. However, the differences in carbohydrate struc- 
ture indicate that the extracellular portion of P- 
glycoprotein in normal and multidrug-resistant cell 
lines can be dissimilar. 
To our knowledge, this is the first example of dif- 
ferential modification of P-glycoprotein from a normal 
tissue compared to that of a multidrug-resistant cell 
line. Further biochemical analysis and in vitro systems 
with gravid uterine epithelial cells will be required to 
evaluate further the significance of such diversity. 
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